<table border="0" cellpadding="3" cellspacing="1" id="i266b5223-3336-4e01-811b-c981c98a7908" width="725" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td>
<list id="i07e621d8-fdcc-4876-8e3e-b936504489eb" listtype="unordered">
<item>
<content stylecode="italics">Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, 
fluoxetine) inhibitors will increase</content> ABILIFY drug concentrations; reduce 
ABILIFY dose by one-half when used concomitantly <linkhtml href="#Section_2.6">(2.6</linkhtml>,<linkhtml href="#Section_7.1"> 7.1)</linkhtml>, except when used 
as adjunctive treatment with antidepressants <linkhtml href="#Section_2.6">(2.6)</linkhtml>
</item>
<item>
<content stylecode="italics">CYP3A4 inducers (eg, carbamazepine) will decrease</content> 
ABILIFY drug concentrations; double ABILIFY dose when used concomitantly <linkhtml href="#Section_2.6">(2.6</linkhtml>,<linkhtml href="#Section_7.1"> 7.1)</linkhtml>
</item>
</list>
<br/>
</td>
</tr>
<tr>
<td>
<br/>See <linkhtml href="#section-19">17</linkhtml> for 
PATIENT COUNSELING INFORMATION and the FDA-approved Medication Guide </td>
</tr>
</tbody>
</table>